A Microdose Cocktail to Evaluate Drug Interactions in Patients with Renal Impairment

Author(s):  
Daniel A. Tatosian ◽  
Ka Lai Yee ◽  
Zufei Zhang ◽  
Kate Mostoller ◽  
Erina Paul ◽  
...  





Author(s):  
Graham Brack ◽  
Penny Franklin ◽  
Jill Caldwell

From the previous chapters you will see that understanding the pharmacological aspects of the drugs you are administering is vital to keeping your patients safe. Nurses need to understand the pharmacodynamics of a medicine, or how it actually works within the body, since this will need to be explained to patients and carers. For example, how will you ensure that a patient understands the importance of taking their treatment for hypertension (especially if they are experiencing no symptoms) if you are unable to explain how the medicine will be working? Similarly, your understanding of the pharmacokinetics (the absorption, distribution, metabolism, and excretion) of individual medicines is vital to ensure compromised patients are not administered inappropriate medicines. For example, you would question the prescribing of a non-steroidal anti-inflammatory drug (NSAID) to a patient with significant renal impairment, because the kidney is essential to the elimination of NSAIDs so the drug could accumulate if the kidneys are not functioning properly. From the point of view of ensuring patient safety, you will need to understand the principles of drug interactions so that you can understand how two medicines (or food and medicine) could interact and be alert to signs that this may be happening. There are several good textbooks dealing with the uses and actions of individual medicines, including interactions. However, these will not be discussed here because at this stage of your career you are not expected to have a detailed knowledge of particular medicines, but rather an understanding of the key principles. As nurses, we are concerned with how the body handles medicines (pharmacokinetics) so that we can see how this may be affected by age, genetics, or illness, and how the actions of medicines may conflict with one another or produce toxicity because their effects are additive. Equally, we need to look at occasions in which two medicines produce the same response by two different routes; such interactions can be beneficial to the patient and avoid having to give large doses of a single medicine because the same result can be achieved with smaller doses of two medicines, thereby reducing the risk of adverse effects.



2016 ◽  
Vol 19 (3) ◽  
pp. A12
Author(s):  
A Saleem ◽  
I Masood ◽  
T.M. Khan ◽  
M Nawaz


2020 ◽  
Vol 109 (1) ◽  
pp. 193-200
Author(s):  
Karthik Lingineni ◽  
Nashid Farhan ◽  
Sarah Kim ◽  
Rodrigo Cristofoletti ◽  
Lori A. Gordon ◽  
...  


2015 ◽  
Vol 63 (12) ◽  
pp. 2643-2644 ◽  
Author(s):  
Lim Jun Pei ◽  
Iris Li Tianzhi ◽  
Wee Shiong Lim




10.36469/9798 ◽  
2017 ◽  
Vol 5 (1) ◽  
pp. 55-64 ◽  
Author(s):  
Ann Kirby ◽  
Aileen Murphy ◽  
Colin Bradley

Background: Prescribing oral anticoagulants for atrial fibrillation patients is becoming more challenging as more alternatives enter the market. While warfarin has dominated the market it is a challenging medicine to use owing to its narrow therapeutic range, increased bleeding risk and requirement for continuous monitoring. The introduction of new oral anticoagulants (NOACs) offers a wider choice but they are more costly and their use also brings additional pharmacological considerations. Objective: This paper investigates if the identified risk factors (renal impairment, hepatic impairment, other co-morbidities & drug interactions) influence GPs’ NOAC prescribing decisions, using a multivariate probit model, while controlling for other GP characteristics. Methods: Employing primary data, collected using a dedicated survey of Irish GPs in November 2015, a multivariate probit is employed. This measures the joint decision making process of prescribing a NOAC based on four risk factors - renal impairment, hepatic impairment, other comorbidities and drug interactions. Results: Younger GPs are more likely to consider ‘other co-morbidities’ and ‘renal impairment’ as important when making NOAC prescribing decisions. Male GPs are more likely to consider ‘other co-morbidities’ and ‘drug interactions’ as important when prescribing NOACs compared to female GPs. Prescribers who have initiated NOACs are more likely to consider ‘renal impairment’ as important compared with non-initiators. Conclusions: Our study highlights the importance for general practitioners prescribing NOACs and caring for patients on oral anticoagulants, of adequate education, of appropriate patient selection and of appropriate monitoring of such patients. While warfarin prescribing remains predominant, NOAC prescribing is increasing. Incorporating the risk factors into prescribing decisions signals responsible prescribing for atrial fibrillation patients. Existing prescribing guidelines/toolkits need to be used in an effective manner.



Sign in / Sign up

Export Citation Format

Share Document